Lyell completes LYL273 manufacturing transfer, pushes back Phase 1/2 data timeline
Lyell now expects additional clinical data and its End-of-Phase 1 FDA meeting for the colorectal cancer CAR T candidate in 2027, not sooner.
SEC filing
Latest
2 stories
Thursday, September 10
Thursday, August 6
Lyell reports Q2 2026 results, updated ronde-cel and LYL273 data
Lyell says its PiNACLE trial in LBCL remains on track and reports the amendment of its LYL273 mCRC study to a Phase 1/2 design after new safety data.
SEC filing